Stockscreener 앱 받기
1.80
28.57%
0.40
Rezolute Inc 주식(RZLT)의 최신 뉴스
Rezolute (NASDAQ:RZLT) Downgraded by Citizens Jmp to Hold - MarketBeat
Investors Buy Large Volume of Rezolute Call Options (NASDAQ:RZLT) - MarketBeat
Guggenheim Issues Pessimistic Forecast for Rezolute (NASDAQ:RZLT) Stock Price - MarketBeat
Jefferies Raises Rezolute Price Target Amid Favorable Data Prospects - timothysykes.com
Rezolute, Inc. (RZLT) Shares Tank 90% Amid Lead Asset Trial FailureHagens Berman Investigating - The Malaysian Reserve
Rezolute (NASDAQ:RZLT) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat
Rezolute (NASDAQ:RZLT) Reaches New 12-Month Low on Analyst Downgrade - MarketBeat
Guggenheim Maintains Rezolute (RZLT) Buy Recommendation - Nasdaq
Jefferies Raises Rezolute’s Price Target Amid Promising Drug Prospects - StocksToTrade
RZLT INVESTIGATION: Rezolute, Inc. Investors Should Contact Block & Leviton LLP To Potentially Recover Losses - TradingView — Track All Markets
Rezolute stock price target slashed by H.C. Wainwright after failed study - Investing.com Canada
Rezolute stock crashes after sole pipeline candidate fails Phase III - Yahoo Finance
Jefferies Lifts Rezolute’s Target amid New Data Anticipation - timothysykes.com
Craig-Hallum downgrades Rezolute stock to Hold on failed Phase III trial - Investing.com Australia
Rezolute price target lowered to $4 from $20 at Maxim - TipRanks
Rezolute decimated on Phase III miss for ersodetug - The Pharma Letter
Rezolute stock price target slashed by Guggenheim after trial failure - Investing.com Nigeria
RZLT Maintains Buy Rating despite Guggenheim's Lowered Price Tar - GuruFocus
Rezolute (RZLT) Stock Update Dec. 12, 2025: Phase 3 sunRIZE Miss Sparks Selloff, Analysts Reset Targets, and 2026 Catalysts - ts2.tech
Rezolute, Inc. (RZLT) Shares Tank 90% Amid Lead Asset Trial Failure -- Hagens Berman Investigating - PR Newswire
Craig-Hallum Downgrades Rezolute to Hold From Buy, Adjusts PT to $2 From $18 - marketscreener.com
Buy Rating Maintained for XOMA Despite Rezolute Bio’s Trial Setback, Future Developments Anticipated - TipRanks
Rezolute (RZLT): HC Wainwright & Co. Significantly Lowers Price Target | RZLT Stock News - GuruFocus
HC Wainwright & Co. Maintains Rezolute (RZLT) Buy Recommendation - Nasdaq
Rezolute price target lowered to $5 from $14 at H.C. Wainwright - TipRanks
What analysts say about Rezolute Inc 6HV1 stockProtective Put Strategies & Rapid Portfolio Growth - earlytimes.in
Praxis tees up another approval filing; Geron turns to layoffs - Yahoo Finance
Rezolute, Inc. (NASDAQ:RZLT) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Rezolute fails phase 3 for RZ358 as placebo response masks 10 mg/kg efficacyCHOSUNBIZ - Chosunbiz
Failed Trials And Missed Targets Send Shares Reeling - Finimize
Rezolute stock hits 52-week low at 1.21 USD despite strong annual gain - Investing.com Canada
Hagens Berman Investigating Rezolute, Inc. (RZLT) as Shares Tank 90% Amid Lead Asset Trial Failure - The AI Journal
Rezolute Inc. (RZLT) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Rezolute stock price target cut to $5 from $17 at BTIG after trial failure - Investing.com Nigeria
Two Biotechs Crash, One Down 88%, On Failed Insulin Drug - Investor's Business Daily
Rezolute, Inc. (RZLT): The "sunRIZE" Post-Mortem & The Tumor Hyperinsulinism Pivot (NASDAQ:RZLT) - Seeking Alpha
Why two Bay Area companies' stocks tumbled on a drug's clinical failureSan Francisco Business Times - The Business Journals
US Stock Market Top Losers Today (December 11, 2025): Oracle’s AI Shock, Rezolute’s 88% Crash and Micro‑Cap Meltdowns - ts2.tech
Rezolute downgraded to Hold from Buy at Craig-Hallum - TipRanks
Rezolute (RZLT): Assessing Valuation After a Year of Strong Share Price Gains - Yahoo Finance
Is RZLT Stock A Hidden Gem? - StocksToTrade
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute - The AI Journal
Rezolute, Inc. Investigated for Securities Fraud ViolationsContact the DJS Law Group to Discuss Your Rights – RZLT - marketscreener.com
Rezolute (RZLT) Stock: Dips Sharply After Phase 3 SunRIZE Trial Disappoints Investors - parameter.io
RZLT: Phase 3 Sunrise study for ersodetug in congenital HI failed to show significant benefit over placebo - TradingView — Track All Markets
Rezolute plunges 90% as Phase 3 sunRIZE trial for low BP fails | Tap to know more | Inshorts - Inshorts
Why Is XOMA Royalty Stock Sinking Thursday? - Benzinga
Biggest Stock Losers Today in the U.S. Market (December 11, 2025): Oracle’s AI Reality Check, Rezolute’s Trial Disaster and Micro‑Cap Carnage - ts2.tech
Rezolute keeps door open for hyperinsulinism drug despite Phase III miss - FirstWord Pharma
Billion Dollar Genetic Disease Stock Crashes, Loses 90% Value As Lead Drug Fails In Trial - Benzinga
Rezolute’s lone drug misses a phase III - BioWorld MedTech
Rezolute (RZLT) Shares Plummet 89% After Phase 3 Trial Setback - GuruFocus
INVESTOR ALERT: Investigation of Rezolute, Inc. (RZLT) by Holzer & Holzer, LLC - GlobeNewswire
Rezolute (RZLT) Downgraded by Wedbush Following Phase 3 Study Re - GuruFocus
Rezolute Downgraded to Hold Amid Disappointing Phase 3 Trial Results for Ersodetug - TipRanks
1.08%
0.91%
자본화:
|
볼륨(24시간):